[1]邓嘉奇,曾祥斌,刘 琳,等.阿托伐他汀联合曲美他嗪在冠心病治疗中的临床疗效及对预后的影响[J].医学信息,2024,37(20):96-99.[doi:10.3969/j.issn.1006-1959.2024.20.018]
　DENG Jiaqi,ZENG Xiangbin,LIU Lin,et al.Clinical Efficacy of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Heart Disease and its Effect on Prognosis[J].Journal of Medical Information,2024,37(20):96-99.[doi:10.3969/j.issn.1006-1959.2024.20.018]
点击复制

阿托伐他汀联合曲美他嗪在冠心病治疗中的临床疗效及对预后的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
96-99
栏目:
论著
出版日期:
2024-10-15

文章信息/Info

Title:
Clinical Efficacy of Atorvastatin Combined with Trimetazidine in the Treatment of Coronary Heart Disease and its Effect on Prognosis
文章编号:
1006-1959（2024）20-0096-04
作者:
邓嘉奇; 曾祥斌; 刘 琳; 曾小玲; 曾丽丽
吉水县人民医院心血管内科，江西 吉水 331600
Author(s):
DENG Jiaqi; ZENG Xiangbin; LIU Lin; ZENG Xiaoling; ZENG Lili
Department of Cardiology,Jishui County People’s Hospital,Jishui 331600,Jiangxi,China
关键词:
冠心病; 阿托伐他汀; 曲美他嗪; 心绞痛; 心功能; 预后生活质量
Keywords:
Coronary heart disease; Atorvastatin; Trimetazidine; Angina pectoris; Cardiac function; Prognostic quality of life
分类号:
R541.4
DOI:
10.3969/j.issn.1006-1959.2024.20.018
摘要:
目的 研究阿托伐他汀联合曲美他嗪在冠心病（CHD）治疗中的临床疗效及对预后的影响。方法 选取2021年1月-2023年1月吉水县人民医院收治的60例CHD患者，经随机数字表法分为对照组（30例）与观察组（30例），对照组给予阿托伐他汀治疗，观察组在其基础上联合曲美他嗪治疗，比较两组临床疗效、心绞痛症状[发作频率、持续时间、疼痛视觉模拟评分（VAS）]、心功能[左室射血分数（LVEF）、左心室舒张末期内径（LVEDD）]、主要不良心血管事件（MACE）、预后生活质量[西雅图心绞痛量表（SAQ）、慢性病患者生命质量测定量表体系之冠心病量表（QLICD-CHD）]。结果 观察组治疗有效率为96.67%，高于对照组的80.00%（P＜0.05）。两组治疗后心绞痛发作频率、持续时间、VAS评分均少于治疗前，且观察组治疗后心绞痛发作频率、持续时间、VAS评分少于对照组（P＜0.05）。两组治疗后LVEF高于治疗前，LVDD低于治疗前，且观察组治疗后LVEF高于对照组，LVDD指标低于对照组（P＜0.05）。观察组MACE发生率为3.33%，小于对照组的23.33%（P＜0.05）。两组治疗后6个月SAQ、QLICD-CHD分数高于治疗前，且观察组SAQ、QLICD-CHD分数高于对照组（P＜0.05）。结论 阿托伐他汀联合曲美他嗪可提高CHD临床疗效，缓解患者心绞痛症状，促进其心功能改善，降低MACE风险，对其预后生活质量的改善具有积极作用。
Abstract:
Objective To study the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of coronary heart disease (CHD) and its effect on prognosis.Methods Sixty patients with CHD admitted to Jishui County People’s Hospital from January 2021 to January 2023 were selected and divided into control group (30 patients) and observation group (30 patients) by random number table method. The control group was treated with atorvastatin, and the observation group was treated with trimetazidine on the basis of the control group. The clinical efficacy, angina pectoris symptoms [attack frequency, duration, Visual Analogue Scale (VAS)], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD)], major adverse cardiovascular events (MACE), prognostic quality of life [Seattle Angina Questionnaire (SAQ), quality of life instruments for chronic diseases-coronary heart diseases (QLICD-CHD)] were compared between the two groups.Results The effective rate of treatment in the observation group was 96.67%, which was higher than 80.00% in the control group (P<0.05). After treatment, the frequency, duration and VAS score of angina pectoris in the two groups were less than those before treatment, and the frequency, duration and VAS score of angina pectoris in the observation group were less than those in the control group (P<0.05). After treatment, LVEF in the two groups was higher than that before treatment, LVDD was lower than that before treatment, and LVEF in the observation group was higher than that in the control group, LVDD index was lower than that in the control group (P<0.05). The incidence of MACE in the observation group was 3.33%, which was lower than 23.33% in the control group (P<0.05). The scores of SAQ and QLICD-CHD in the two groups at 6 months after treatment were higher than those before treatment, and the scores of SAQ and QLICD-CHD in the observation group were higher than those in the control group (P<0.05).Conclusion Atorvastatin combined with trimetazidine can improve the clinical efficacy of CHD, relieve the symptoms of angina pectoris, promote the improvement of cardiac function, reduce the risk of MACE, and have a positive effect on the improvement of prognosis and quality of life.

参考文献/References:

[1]李倩,石咏梅.曲美他嗪联合阿托伐他汀钙治疗老年ICM心衰的疗效研究[J].贵州医药,2022,46(11):1696-1697.[2]邢巧莉,薛玉刚.曲美他嗪结合阿托伐他汀治疗冠心病对患者心功能不良反应的影响[J].山西医药杂志,2022,51(14):1615-1618.[3]张建辉.曲美他嗪联合阿托伐他汀钙对心绞痛血管内皮功能及炎症反应的影响[J].中国临床医生杂志,2020,48(11):1300-1303.[4]季俭,王敏燕,卢英民.曲美他嗪联合瑞舒伐他汀用于冠心病合并心力衰竭的临床疗效[J].武汉大学学报(医学版),2020,41(6):1007-1012.[5]唐小丰.曲美他嗪与阿托伐他汀联合治疗对冠心病心力衰竭患者心功能及对脑钠肽水平的影响[J].中国药物与临床,2020,20(16):2756-2758.[6]李砚杰.曲美他嗪联合阿托伐他汀治疗53例冠心病患者疗效观察[J].上海医药,2020,41(3):20-23.[7]钱仁怡.阿托伐他汀钙联合曲美他嗪治疗对冠心病患者内皮功能 炎性因子以及心功能影响的关系研究[J].中国药物与临床,2019,19(24):4358-4360.[8]梁财旺.曲美他嗪联合阿托伐他汀治疗稳定型心绞痛病人的临床疗效及对心功能的影响[J].中西医结合心脑血管病杂志,2019,17(22):3637-3638.[9]王斌,李毅,韩雅玲.稳定性冠心病诊断与治疗指南[J].中华心血管病杂志,2018,46(9):680-694.[10]刘呈楠.冠心病患者应用瑞舒伐他汀联合曲美他嗪治疗对并发症发生率的影响[J].重庆医学,2022,51(1):282-284.[11]张冬梅,张军,李恭.盐酸曲美他嗪胶囊联合阿托伐他汀钙片对冠心病患者血小板活化功能和血管内皮功能的影响[J].药物评价研究,2019,42(1):113-116.[12]郑晓辉,刘洪强,张洪磊.阿托伐他汀钙片联合曲美他嗪治疗心绞痛的临床疗效[J].实用心脑肺血管病杂志,2018,26(11):100-102.[13]侯江红,李军农.阿托伐他汀与曲美他嗪联用对冠心病患者的心肌保护作用及对凝血系统功能的影响[J].中国医刊,2018,53(11):1223-1225.[14]邹何慧.曲美他嗪联合阿托伐他汀治疗老年冠心病心功能不全患者的临床观察[J].中国卫生检验杂志,2018,28(10):1259-1261.[15]左红,魏亚静,侯文兵,等.曲美他嗪联合阿托伐他汀对冠心病患者心功能及炎症因子的影响[J].药物评价研究,2018,41(5):841-843.[16]冯艳林,李毅,马瑞,等.曲美他嗪结合阿托伐他汀对冠心病患者临床疗效及炎性因子表达影响的研究[J].中国心血管病研究,2018,16(7):651-654.[17]陈洁.阿托伐他汀联合曲美他嗪治疗心肌缺血的疗效观察[J].中西医结合心脑血管病杂志,2018,16(2):250-251.[18]雷斌.曲美他嗪联合阿托伐他汀对冠心病心绞痛的治疗效果分析[J].中国急救医学,2018,38(1):68-68.[19]杨军,许波,冯维,等.阿托伐他汀联合曲美他嗪治疗冠心病疗效及对血管内皮功能的影响[J].中国临床保健杂志,2019,22(3):383-385.[20]杨瑞金,肖扬.曲美他嗪联合阿托伐他汀治疗冠心病的临床效果[J].山西医药杂志,2021,50(1):75-77.

相似文献/References:

[1]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,31(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
　YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Journal of Medical Information,2018,31(20):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[2]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,31(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
　ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Journal of Medical Information,2018,31(20):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[3]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,31(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
　ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Journal of Medical Information,2018,31(20):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[4]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,31(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
　ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Journal of Medical Information,2018,31(20):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[5]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,31(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
　XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Journal of Medical Information,2018,31(20):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[6]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,31(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
　WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Journal of Medical Information,2018,31(20):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[7]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,31(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
　MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Journal of Medical Information,2018,31(20):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[8]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,31(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
　YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Journal of Medical Information,2018,31(20):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[9]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
　LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Journal of Medical Information,2018,31(20):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[10]田跃雷.冠心病介入治疗后再狭窄的中西医防治[J].医学信息,2022,35(09):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
　TIAN Yue-lei.Prevention and Treatment of Restenosis After Percutaneous Coronary Intervention with Chinese and Western Medicine[J].Journal of Medical Information,2022,35(20):46.[doi:10.3969/j.issn.1006-1959.2022.09.011]
[11]王 毅.阿托伐他汀联合曲美他嗪治疗冠心病的临床效果评价[J].医学信息,2018,31(13):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
　WANG Yi.Clinical Evaluation of Atto Vastatin Combined with Trimetazidine in the Treatment of Coronary Atherosclerotic Heart Disease[J].Journal of Medical Information,2018,31(20):139.[doi:10.3969/j.issn.1006-1959.2018.13.041]
[12]高占群,李 霜,刘 杨.苯那普利联合阿托伐他汀治疗冠心病合并2型糖尿病 心功能不全的临床效果[J].医学信息,2019,32(17):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
　GAO Zhan-qun,LI Shuang,LIU Yang.Clinical Effect of Benazepril Combined with Atorvastatin in the Treatment of Coronary Heart Disease Complicated with Type 2 Diabetes with Cardiac Insufficiency[J].Journal of Medical Information,2019,32(20):135.[doi:10.3969/j.issn.1006-1959.2019.17.044]
[13]师存莉,陈 蓉.阿托伐他汀联合冠心舒通胶囊对糖尿病合并冠心病患者心律失常的疗效及对血脂与凝血功能的影响[J].医学信息,2022,35(06):159.[doi:10.3969/j.issn.1006-1959.2022.06.041]
　SHI Cun-li,CHEN Rong.Effect of Atorvastatin Combined with Guanxinshutong Capsule on Arrhythmia and Blood Lipid and Coagulation Function in Diabetic Patients with Coronary Heart Disease[J].Journal of Medical Information,2022,35(20):159.[doi:10.3969/j.issn.1006-1959.2022.06.041]

更新日期/Last Update: 1900-01-01